Company Description
Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland.
The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder.
Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The Charcot"Marie"Tooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A.
The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.
| Country | Switzerland |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 23 |
| CEO | Timothy Mark Dyer |
Contact Details
Address: Chemin Des Mines 9 Geneva, V8 CH-1202 Switzerland | |
| Phone | 01141228841555 |
| Website | addextherapeutics.com |
Stock Details
| Ticker Symbol | ADXN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001574232 |
| CUSIP Number | 00654J107 |
| ISIN Number | US00654J2069 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Timothy Mark Dyer | Co-Founder, Chief Executive Officer and Director |
| Dr. Roger G. Mills M.D. | Chief Medical Officer and Director |
| Lénaic Teyssédou | Head of Finance |
| Dr. Jean-Philippe Rocher Ph.D. | Head of Discovery - Chemistry |
| Dr. Robert Lutjens | Head of Discovery - Biology |
| Dr. Mikhail Kalinichev Ph.D. | Head of Translational Science |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 29, 2024 | 6-K | Report of foreign issuer |
| Apr 24, 2024 | 424B3 | Prospectus |
| Apr 22, 2024 | EFFECT | Notice of Effectiveness |
| Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
| Apr 18, 2024 | 20-F | Annual and transition report of foreign private issuers |
| Apr 18, 2024 | 6-K | Report of foreign issuer |
| Apr 3, 2024 | 6-K | Report of foreign issuer |
| Jan 30, 2024 | 424B5 | Filing |
| Jan 30, 2024 | 6-K | Report of foreign issuer |
| Dec 21, 2023 | 6-K/A | Filing |